Skip to main content
Top

10-05-2024 | Esophageal Varices | Original Article―Liver, Pancreas, and Biliary Tract

ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis

Authors: Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Koichi Takaguchi, Makoto Nakamuta, Tsunamasa Watanabe, Asahiro Morishita, Joji Tani, Hironao Okubo, Atsushi Hiraoka, Akito Nozaki, Makoto Chuma, Kazuhito Kawata, Haruki Uojima, Chikara Ogawa, Toru Asano, Shigeru Mikami, Keizo Kato, Kentaro Matsuura, Tadashi Ikegami, Toru Ishikawa, Kunihiko Tsuji, Toshifumi Tada, Akemi Tsutsui, Tomonori Senoh, Michika Kitamura, Tomomi Okubo, Taeang Arai, Motoyuki Kohjima, Kiyoshi Morita, Takehiro Akahane, Hiroki Nishikawa, Motoh Iwasa, Yasuhito Tanaka, Katsuhiko Iwakiri

Published in: Journal of Gastroenterology

Login to get access

Abstract

Background

This study aimed to clarify the morphological changes in esophageal varices after achieving sustained virological response (SVR) with direct-acting antivirals (DAAs) in patients with cirrhosis.

Methods

A total of 243 patients underwent esophagogastroduodenoscopy before DAA treatment and after achieving SVR. Morphological changes in esophageal varices were investigated using esophagogastroduodenoscopy.

Results

This study comprised 125 males and 118 females with a median age of 68 years. Esophageal varices at baseline were classified into no varix in 155 (63.8%), F1 in 59 (24.3%), F2 in 25 (10.3%) and F3 in 4 (1.6%) patients. The improvement, unchanged, and aggravation rates of esophageal varices after SVR were 11.9%, 73.3%, and 14.8%, respectively. High ALBI score at SVR12 was an independent factor associated with post-SVR esophageal varices aggravation (p = 0.045). Time-dependent receiver operating characteristic (ROC) curve analysis revealed a cut-off value of − 2.33 for ALBI score at SVR12 in predicting post-SVR esophageal varices aggravation. Of the 155 patients without esophageal varices at baseline, 17 developed de novo post-SVR esophageal varices. High ALBI score at SVR12 was a significant independent factor associated with de novo post-SVR esophageal varices (p = 0.046). ROC curve analysis revealed a cut-off value of − 2.65 for ALBI score at SVR12 in predicting de novo post-SVR esophageal varices.

Conclusions

Patients with cirrhosis can experience esophageal varices aggravation or de novo esophageal varices, despite achieving SVR. In particular, patients with high ALBI score at SVR12 have a high likelihood of developing post-SVR esophageal varices aggravation or de novo post-SVR esophageal varices.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008;134:1715–28.CrossRefPubMed Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008;134:1715–28.CrossRefPubMed
2.
3.
go back to reference Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725–49.CrossRefPubMed Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725–49.CrossRefPubMed
4.
go back to reference Yoshida H, Shimizu T, Yoshioka M, Taniai N. Management of portal hypertension based on portal hemodynamics. Hepatol Res. 2021;51:251–62.CrossRefPubMed Yoshida H, Shimizu T, Yoshioka M, Taniai N. Management of portal hypertension based on portal hemodynamics. Hepatol Res. 2021;51:251–62.CrossRefPubMed
5.
go back to reference Enomoto H, Ueno Y, Hiasa Y, et al. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol. 2021;56:158–67.CrossRefPubMed Enomoto H, Ueno Y, Hiasa Y, et al. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol. 2021;56:158–67.CrossRefPubMed
6.
go back to reference Atsukawa M, Tsubota A, Toyoda H, et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 2019;49:1230–41.CrossRefPubMed Atsukawa M, Tsubota A, Toyoda H, et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 2019;49:1230–41.CrossRefPubMed
7.
go back to reference Nozaki A, Atsukawa M, Kondo C, et al. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. 2020;14:225–38.CrossRefPubMed Nozaki A, Atsukawa M, Kondo C, et al. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. 2020;14:225–38.CrossRefPubMed
8.
go back to reference Itokawa N, Atsukawa M, Tsubota A, et al. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: a multicenter study. Hepatol Res. 2019;49:125–35.CrossRefPubMed Itokawa N, Atsukawa M, Tsubota A, et al. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: a multicenter study. Hepatol Res. 2019;49:125–35.CrossRefPubMed
9.
go back to reference Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87–95.CrossRefPubMed Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87–95.CrossRefPubMed
10.
go back to reference El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154:2111–21.CrossRefPubMed El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154:2111–21.CrossRefPubMed
11.
go back to reference Atsukawa M, Tsubota A, Kondo C, et al. Real-world clinical application of 12-week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Infect Dis Ther. 2020;9:851–66.CrossRefPubMedPubMedCentral Atsukawa M, Tsubota A, Kondo C, et al. Real-world clinical application of 12-week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Infect Dis Ther. 2020;9:851–66.CrossRefPubMedPubMedCentral
12.
go back to reference Atsukawa M, Tsubota A, Kondo C, et al. Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022;52:235–46.CrossRefPubMed Atsukawa M, Tsubota A, Kondo C, et al. Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022;52:235–46.CrossRefPubMed
13.
go back to reference Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67–77.CrossRefPubMed Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67–77.CrossRefPubMed
14.
go back to reference Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120–32.CrossRefPubMed Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120–32.CrossRefPubMed
15.
go back to reference Sano T, Amano K, Ide T, et al. A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2023;53:26–34.CrossRefPubMed Sano T, Amano K, Ide T, et al. A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2023;53:26–34.CrossRefPubMed
16.
go back to reference Kumada T, Toyoda H, Yasuda S, et al. Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus. Infect Dis Ther. 2021;10:1001–13.CrossRefPubMedPubMedCentral Kumada T, Toyoda H, Yasuda S, et al. Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus. Infect Dis Ther. 2021;10:1001–13.CrossRefPubMedPubMedCentral
17.
go back to reference Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692–9.CrossRefPubMed Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692–9.CrossRefPubMed
18.
go back to reference Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017;153:1273–83.CrossRefPubMed Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017;153:1273–83.CrossRefPubMed
19.
go back to reference Nagaoki Y, Imamura M, Teraoka Y, et al. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res. 2020;50:1222–33.CrossRefPubMed Nagaoki Y, Imamura M, Teraoka Y, et al. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res. 2020;50:1222–33.CrossRefPubMed
20.
go back to reference Puigvehí M, Londoño MC, Torras X, et al. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. J Gastroenterol. 2020;55:205–16.CrossRefPubMed Puigvehí M, Londoño MC, Torras X, et al. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. J Gastroenterol. 2020;55:205–16.CrossRefPubMed
21.
go back to reference Tajiri T, Yoshida H, Obara K, et al. General rules for recording endoscopic findings of esophagogastric varices. Dig Endosc. 2010;22:1–9.CrossRefPubMed Tajiri T, Yoshida H, Obara K, et al. General rules for recording endoscopic findings of esophagogastric varices. Dig Endosc. 2010;22:1–9.CrossRefPubMed
22.
go back to reference Okaniwa S, Hirai T, Ogawa M, et al. Manual for abdominal ultrasound in cancer screening and health checkups. J Med Ultrason. 2023;50:5–49.CrossRef Okaniwa S, Hirai T, Ogawa M, et al. Manual for abdominal ultrasound in cancer screening and health checkups. J Med Ultrason. 2023;50:5–49.CrossRef
23.
go back to reference Pfisterer N, Schwarz M, Jachs M, et al. Endoscopic band ligation is safe despite low platelet count and high INR. Hepatol Int. (in press) Pfisterer N, Schwarz M, Jachs M, et al. Endoscopic band ligation is safe despite low platelet count and high INR. Hepatol Int. (in press)
24.
go back to reference Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35.CrossRefPubMed Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35.CrossRefPubMed
25.
go back to reference EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. European Association for the Study of the Liver. J Hepatol. 2018;69:406–60. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. European Association for the Study of the Liver. J Hepatol. 2018;69:406–60.
26.
go back to reference Merkel C, Bolognesi M, Berzigotti A, et al. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. J Hepatol. 2010;52:45–53.CrossRefPubMed Merkel C, Bolognesi M, Berzigotti A, et al. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. J Hepatol. 2010;52:45–53.CrossRefPubMed
27.
go back to reference Allaire M, Campion B, Demory A, et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:346–56.CrossRefPubMed Allaire M, Campion B, Demory A, et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:346–56.CrossRefPubMed
28.
go back to reference de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.CrossRefPubMed de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.CrossRefPubMed
Metadata
Title
ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis
Authors
Masanori Atsukawa
Akihito Tsubota
Chisa Kondo
Hidenori Toyoda
Koichi Takaguchi
Makoto Nakamuta
Tsunamasa Watanabe
Asahiro Morishita
Joji Tani
Hironao Okubo
Atsushi Hiraoka
Akito Nozaki
Makoto Chuma
Kazuhito Kawata
Haruki Uojima
Chikara Ogawa
Toru Asano
Shigeru Mikami
Keizo Kato
Kentaro Matsuura
Tadashi Ikegami
Toru Ishikawa
Kunihiko Tsuji
Toshifumi Tada
Akemi Tsutsui
Tomonori Senoh
Michika Kitamura
Tomomi Okubo
Taeang Arai
Motoyuki Kohjima
Kiyoshi Morita
Takehiro Akahane
Hiroki Nishikawa
Motoh Iwasa
Yasuhito Tanaka
Katsuhiko Iwakiri
Publication date
10-05-2024
Publisher
Springer Nature Singapore
Published in
Journal of Gastroenterology
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-024-02109-8
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine